Skip to content
10-Q

Quarterly Report

FibroBiologics, Inc. FBLG

0001193125-26-197858

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 5.21M sh
Shares Diluted Q1 2026 · Mar 31, 2026 3.77M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1.83M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $43K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.36M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.28M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.48M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.89M
Stockholders Equity Q1 2026 · Mar 31, 2026 $2.6M
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.16M
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.35M
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.74M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.83M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.76M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.34M
Total Liabilities Q1 2026 · Dec 31, 2025 $3.46M
Current Assets Q1 2026 · Mar 31, 2026 $2.91M
Current Assets Q1 2026 · Dec 31, 2025 $6.35M
Total Assets Q1 2026 · Mar 31, 2026 $5.94M
Total Assets Q1 2026 · Dec 31, 2025 $9.62M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.33
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.71
Eps Basic Q1 2026 · Mar 31, 2026 −$1.33
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.71
Sga Expense Q1 2026 · Mar 31, 2026 $2.12M
Sga Expense Q1 2026 · Mar 31, 2025 $2.75M
Rd Expense Q1 2026 · Mar 31, 2026 $2.95M
Rd Expense Q1 2026 · Mar 31, 2025 $1.78M
Net Income Q1 2026 · Mar 31, 2026 −$5M
Net Income Q1 2026 · Mar 31, 2025 −$4.97M
Operating Income Q1 2026 · Mar 31, 2026 −$5.07M
Operating Income Q1 2026 · Mar 31, 2025 −$4.53M